MCID: MYT002
MIFTS: 50

Myotonic Dystrophy

Categories: Endocrine diseases, Eye diseases, Fetal diseases, Genetic diseases, Muscle diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Myotonic Dystrophy

MalaCards integrated aliases for Myotonic Dystrophy:

Name: Myotonic Dystrophy 74 52 25 58 36 29 54 6 71
Dystrophia Myotonica 52 25
Myotonia Dystrophica 52 25
Myotonia Atrophica 52 25
Myotonic Dystrophy 1 71

Characteristics:

Orphanet epidemiological data:

58
myotonic dystrophy
Prevalence: >1/1000,1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (Italy),1-9/100000 (Japan),1-9/100000 (Ireland),1-5/10000 (Croatia),1-5/10000 (New Zealand),1-5/10000 (Finland),1-9/100000 (Norway),1-5/10000 (Spain),1-9/100000 (United States);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

KEGG 36 H00568
MESH via Orphanet 44 D009223
ICD10 via Orphanet 33 G71.1
UMLS via Orphanet 72 C0027126 C0410226
Orphanet 58 ORPHA206647
UMLS 71 C0027126 C3250443

Summaries for Myotonic Dystrophy

Genetics Home Reference : 25 Myotonic dystrophy is part of a group of inherited disorders called muscular dystrophies. It is the most common form of muscular dystrophy that begins in adulthood. Myotonic dystrophy is characterized by progressive muscle wasting and weakness. People with this disorder often have prolonged muscle contractions (myotonia) and are not able to relax certain muscles after use. For example, a person may have difficulty releasing their grip on a doorknob or handle. Also, affected people may have slurred speech or temporary locking of their jaw. Other signs and symptoms of myotonic dystrophy include clouding of the lens of the eye (cataracts) and abnormalities of the electrical signals that control the heartbeat (cardiac conduction defects). In affected men, hormonal changes may lead to early balding and an inability to father a child (infertility). The features of this disorder often develop during a person's twenties or thirties, although they can occur at any age. The severity of the condition varies widely among affected people, even among members of the same family. There are two major types of myotonic dystrophy: type 1 and type 2. Their signs and symptoms overlap, although type 2 tends to be milder than type 1. The muscle weakness associated with type 1 particularly affects the lower legs, hands, neck, and face. Muscle weakness in type 2 primarily involves the muscles of the neck, shoulders, elbows, and hips. The two types of myotonic dystrophy are caused by mutations in different genes. A variation of type 1 myotonic dystrophy, called congenital myotonic dystrophy, is apparent at birth. Characteristic features include weak muscle tone (hypotonia), an inward- and upward-turning foot (clubfoot), breathing problems, delayed development, and intellectual disability. Some of these health problems can be life-threatening.

MalaCards based summary : Myotonic Dystrophy, also known as dystrophia myotonica, is related to myotonic dystrophy 1 and myotonic dystrophy 2, and has symptoms including excessive daytime somnolence and weakness. An important gene associated with Myotonic Dystrophy is DMPK (DM1 Protein Kinase). The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include testes, skeletal muscle and heart, and related phenotypes are Increased cell viability after pRB stimulation and muscle

NIH Rare Diseases : 52 Myotonic dystrophy is a disease that affects the muscles and other body systems. It is the most common form of muscular dystrophy that begins in adulthood, usually in a person's 20s or 30s. This disease is characterized by progressive muscle loss and weakness. Myotonic dystrophy may be further classified into two types, and the two types may affect different muscles. People with myotonic dystrophy usually have prolonged muscle tensing (myotonia ) and are not able to relax certain muscles after use. The severity of the disease may vary among affected people, even among members of the same family. Myotonic dystrophy is caused by mutations (changes) in the DMPK gene or the CNBP (ZNF9) gene depending on the specific type of myotonic dystrophy. The disease is inherited in an autosomal dominant manner. Myotonic dystrophy may be diagnosed when a healthcare provider observes signs and symptoms of the disease, and the diagnosis may be confirmed with tests of muscle function and genetic testing . Treatment is based on each person's specific signs and symptoms and may include physical therapy , pain management with medication, and consultation with specialists.

KEGG : 36 Myotonic dystrophy (DM) is a complex multisystemic disorder linked to two different genetic loci. DM1 is caused by an expansion of a CTG repeat located in the 3' untranslated region (UTR) of DMPK. DM2 is caused by an unstable CCTG repeat in intron 1 of ZNF9. Therefore, both DMs are caused by a repeat expansion in a region transcribed into RNA but not translated into protein. The mutant RNA transcripts aberrantly affect the splicing of the same target RNAs, such as chloride channel 1 (ClC-1) and insulin receptor (INSR), resulting in their shared myotonia and insulin resistance. Affected individuals express highly heterogeneous, multisystemic symptoms including myotonia (muscle hyperexcitability), progressive muscle weakness and wasting, cataract development, testicular atrophy, and cardiac conduction defects. It has an autosomal dominant mode of inheritance and disease severity generally correlates with repeat length.

Wikipedia : 74 Myotonic dystrophy is a long-term genetic disorder that affects muscle function. Symptoms include... more...

Related Diseases for Myotonic Dystrophy

Diseases in the Myotonic Dystrophy family:

Myotonic Dystrophy 1 Myotonic Dystrophy 2

Diseases related to Myotonic Dystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 622)
# Related Disease Score Top Affiliating Genes
1 myotonic dystrophy 1 31.8 SIX5 MBNL3 MBNL2 MBNL1 DMPK CNBP
2 myotonic dystrophy 2 31.7 SIX5 MBNL3 MBNL2 MBNL1 DMPK CNBP
3 myotonia 31.5 DMPK CNBP CLCN1
4 myotonia congenita 30.2 LOC108644431 DMPK CNBP CLCN1
5 autosomal dominant cerebellar ataxia 30.0 MBNL1 DMPK CNBP CELF1
6 neuromuscular disease 30.0 MBNL1 HSPB2 DMPK CNBP CELF1
7 fuchs' endothelial dystrophy 29.9 MBNL2 MBNL1 DMPK
8 spinocerebellar ataxia 8 29.8 MBNL1 DMPK CNBP CELF1
9 hyperkalemic periodic paralysis 29.7 DMPK CNBP CLCN1
10 cataract 29.6 SIX5 MBNL1 HSPB2 DMPK CNBP
11 fragile x-associated tremor/ataxia syndrome 29.5 MBNL1 DMPK CNBP CELF1
12 huntington disease-like 2 29.4 MBNL1 DMPK CNBP CELF1
13 muscular disease 29.1 MBNL2 MBNL1 DMPK CNBP CLCN1 CELF1
14 myotonic disease 28.0 SIX5 MBNL3 MBNL2 MBNL1 DMPK CNBP
15 pilomatrixoma 11.8
16 hypotonia 11.7
17 dysphagia 11.7
18 myotonic cataract 11.6
19 swallowing disorders 11.6
20 nondystrophic myotonia 11.6
21 floppy infant syndrome 11.3
22 infantile hypotonia 11.3
23 muscular dystrophy 11.1
24 myopathy 10.9
25 muscular atrophy 10.8
26 respiratory failure 10.7
27 atrioventricular block 10.7
28 sleep apnea 10.7
29 cardiac conduction defect 10.6
30 neuropathy 10.6
31 hypogonadism 10.6
32 hyperinsulinism 10.6
33 hypogonadotropism 10.6
34 progressive familial heart block, type ia 10.6
35 ptosis 10.6
36 polyhydramnios 10.6
37 hypersomnia 10.5
38 glucose intolerance 10.5
39 left bundle branch hemiblock 10.5
40 huntington disease 10.5
41 atrial standstill 1 10.5
42 ataxia and polyneuropathy, adult-onset 10.5
43 sleep disorder 10.5
44 peripheral nervous system disease 10.5
45 muscular dystrophy, duchenne type 10.5
46 orthostatic intolerance 10.5
47 dilated cardiomyopathy 10.5
48 hyperparathyroidism 10.4
49 thymoma, familial 10.4
50 ventricular fibrillation, paroxysmal familial, 1 10.4

Graphical network of the top 20 diseases related to Myotonic Dystrophy:



Diseases related to Myotonic Dystrophy

Symptoms & Phenotypes for Myotonic Dystrophy

UMLS symptoms related to Myotonic Dystrophy:


excessive daytime somnolence, weakness

GenomeRNAi Phenotypes related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell viability after pRB stimulation GR00230-A-1 8.8 CDC42BPA CDC42BPB DMPK

MGI Mouse Phenotypes related to Myotonic Dystrophy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.1 CLCN1 DMPK MBNL1 MBNL2 MBNL3 SIX5

Drugs & Therapeutics for Myotonic Dystrophy

Drugs for Myotonic Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
3
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
4
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
5
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
6 Dopamine Agents Phase 2, Phase 3
7 Neurotransmitter Agents Phase 2, Phase 3
8 Dopamine Uptake Inhibitors Phase 2, Phase 3
9 Sodium Channel Blockers Phase 3
10 Diuretics, Potassium Sparing Phase 3
11 Hormones Phase 3
12 Anticonvulsants Phase 3
13 Antipsychotic Agents Phase 3
14 Tranquilizing Agents Phase 3
15 Psychotropic Drugs Phase 3
16 Calcium, Dietary Phase 3
17 Central Nervous System Depressants Phase 3
18 calcium channel blockers Phase 3
19 DHEA (Dehydroepiandrosterone) Phase 2, Phase 3
20 Adjuvants, Immunologic Phase 2, Phase 3
21 Immunologic Factors Phase 2, Phase 3
22
Zinc Approved, Investigational Phase 2 7440-66-6 32051
23
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
24
Mecasermin Approved, Investigational Phase 1, Phase 2 68562-41-4
25
Clarithromycin Approved Phase 2 81103-11-9 84029
26 Hypoglycemic Agents Phase 2
27 Complement Factor I Phase 2
28 Anti-Arrhythmia Agents Phase 2
29 insulin Phase 1, Phase 2
30 Mitogens Phase 1, Phase 2
31 Insulin, Globin Zinc Phase 1, Phase 2
32 Cytochrome P-450 CYP3A Inhibitors Phase 2
33 Cytochrome P-450 Enzyme Inhibitors Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Anti-Bacterial Agents Phase 2
36 Anti-Infective Agents Phase 2
37
Ranolazine Approved, Investigational Phase 1 142387-99-3, 95635-55-5 56959
38
Modafinil Approved, Investigational 68693-11-8 4236
39
Fibrinolysin Investigational 9004-09-5
40 Liver Extracts
41 alpha-2-Antiplasmin
42 Antifibrinolytic Agents
43 Anticoagulants
44 Hemostatics
45 Coagulants
46 Lupus Coagulation Inhibitor
47 Pigment epithelium-derived factor
48 Plasminogen Inactivators
49 Plasminogen
50 Plasminogen Activator Inhibitor 1

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1) Unknown status NCT00127582 Phase 3
2 Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1) Unknown status NCT01225614 Phase 3
3 Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 Completed NCT01421992 Phase 2, Phase 3 Methylphenidate;Placebo
4 Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study Completed NCT01939561 Phase 3 Lamotrigine;Placebo
5 Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3 dehydroepiandrosterone 100 and 400 mg
6 A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy Not yet recruiting NCT03692312 Phase 2, Phase 3 Tideglusib;Placebo
7 A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1 Unknown status NCT00577577 Phase 2 rhIGF-I/rhIGFBP-3;placebo
8 A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy Completed NCT02858908 Phase 2 Tideglusib
9 A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1) Completed NCT01406873 Phase 2 Mexiletine;Placebo
10 A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1 Completed NCT02312011 Phase 1, Phase 2 IONIS-DMPKRx;Placebo
11 Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Completed NCT00233519 Phase 1, Phase 2 SomatoKine/IPLEX
12 Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes Recruiting NCT04026958 Phase 2 Clarithromycin;Placebo
13 Intramuscular Transplantation of Autologous Muscle Derived Stem Cell(MDSC) and Adipose Derived Mesenchymal Stem Cells (AD-MSC) in Patients With Facioscapulohumeral Dystrophy (FSHD), Phase I Clinical Trial Unknown status NCT02208713 Phase 1
14 Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies. Unknown status NCT00674843 Phase 1
15 Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1 Completed NCT02251457 Phase 1 Ranolazine
16 Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults With Myotonic Dystrophy Type 1 Recruiting NCT03959189 Phase 1 ERX-963;Placebo
17 Function, Structure and Quality of Striated Muscles in Patients With Muscular Diseases - an MRI Study on Pompe Disease and Dystrophia Myotonica Unknown status NCT02708784
18 Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy Unknown status NCT02269865
19 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Unknown status NCT02375087
20 Four Weeks Withdrawal of Non-invasive Ventilation (NIV) in Patients With Myotonic Dystrophy: Cardiovascular, Metabolic and Daytime Vigilance Induced Changes Unknown status NCT00745238
21 NON-INVASIVE PRENATAL TESTING (NIPT) OF FETAL SINGLE-GENE DISORDERS IN MATERNAL BLOOD Unknown status NCT02339402
22 Validation of a German Language Screening Questionnaire for Symptoms of Respiratory Muscle Weakness and Sleep-disordered Breathing in Patients With Neuromuscular Disorders Unknown status NCT02833168
23 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Completed NCT04018820
24 Effects of a Multiple Component Training Program on Muscles, Maximal Muscle Strength, Endurance and Functional Performance in Adults With Myotonic Dystrophy Type 1: A Pilot Study Completed NCT04001920
25 Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study Completed NCT02729597
26 Cardiac and Respiratory Prognostic Factors in Patients With Myotonic Dystrophy Type 1 Completed NCT01136330
27 A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1 Completed NCT02308657
28 Prospective Randomized Controlled Single Blind Study of Efficacy and Tolerance of AVAPS Mode Compared to Bilevel Pressure Ventilation un Adult Patients With Myotonic Dystrophy Completed NCT01530841
29 Incidence and Predictors of Venous Thromboembolism in Myotonic Dystrophy Completed NCT03141749
30 Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life Completed NCT03589677
31 Myotonic Dystrophy:Muscle Wasting and Altered Metabolism Completed NCT00004769
32 Lung Function Impairment and Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Completed NCT01242007
33 A Registry of Arrhythmias in Myotonic Muscular Dystrophy Completed NCT00622453
34 Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life Standards, a Target Identification Collaboration Completed NCT02118779
35 Pulmonary Hypertension--Mechanisms and Family Registry Completed NCT00005357
36 Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Recruiting NCT03981575
37 The UK National Registry for Myotonic Dystrophy Recruiting NCT04003363
38 Effect of Noninvasive Mechanical Ventilation on Ventilatory Response in Patients With Myotonic Dystrophy Type 1 Recruiting NCT02880735
39 The Electrophysiological Study Guided ICD Strategy in Prevention of Arrhythmic Cardiac Death in Myotonic Dystrophy Type 1 Patients With Conduction System Disease (ACADEMY 1 Study) Recruiting NCT03784586
40 Venous Thromboembolism in Myotonic Dystrophy Type 1 Recruiting NCT03424460
41 Functional and Cellular Benefits of Aerobic Exercise in Myotonic Dystrophy Type 1 Patients Recruiting NCT04187482
42 Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years Recruiting NCT03764150
43 Myotonic Dystrophy Family Registry Recruiting NCT02398786
44 Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy Recruiting NCT03059264
45 National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members Recruiting NCT00082108
46 Assessing Clinical Endpoint and Biomarkers in Myotonic Dystrophy Type-1 and Type-2 Recruiting NCT03867435
47 Observational Trial in Myotonic Dystrophy Type 2 to Define Specific Clinical Outcome Measures Recruiting NCT03603171
48 A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives Recruiting NCT01931644
49 Non Invasive Prenatal Diagnosis on Isolated Circulating Fetal Trophoblastic Cells (CFTC) for Triplet Repeat Diseases Recruiting NCT03087526
50 Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials Active, not recruiting NCT02831504

Search NIH Clinical Center for Myotonic Dystrophy

Genetic Tests for Myotonic Dystrophy

Genetic tests related to Myotonic Dystrophy:

# Genetic test Affiliating Genes
1 Myotonic Dystrophy 29

Anatomical Context for Myotonic Dystrophy

MalaCards organs/tissues related to Myotonic Dystrophy:

40
Testes, Skeletal Muscle, Heart, Brain, Eye, Thyroid, Liver

Publications for Myotonic Dystrophy

Articles related to Myotonic Dystrophy:

(show top 50) (show all 5126)
# Title Authors PMID Year
1
Myotonic dystrophy: candidate small molecule therapeutics. 61 52
28780071 2017
2
Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. 61 52
28803727 2017
3
Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. 61 54
20138216 2010
4
Molecular aptamer beacon for myotonic dystrophy kinase-related Cdc42-binding kinase alpha. 61 54
20188990 2010
5
Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. 61 54
20406734 2010
6
Human MRCKalpha is regulated by cellular iron levels and interferes with transferrin iron uptake. 54 61
20188707 2010
7
Muscleblind1, but not Dmpk or Six5, contributes to a complex phenotype of muscular and motivational deficits in mouse models of myotonic dystrophy. 61 54
20360842 2010
8
Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. 54 61
20051426 2010
9
Possible de novo CTG repeat expansion in the DMPK gene of a patient with cardiomyopathy. 61 54
20074967 2010
10
CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2. 61 54
20458885 2010
11
Pathogenic mechanisms of myotonic dystrophy. 54 61
19909263 2009
12
MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. 61 54
19934222 2009
13
A tail-anchored myotonic dystrophy protein kinase isoform induces perinuclear clustering of mitochondria, autophagy, and apoptosis. 61 54
19946639 2009
14
RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study. 54 61
19864209 2009
15
Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction. 61 54
19184181 2009
16
High-fat diet induced adiposity and insulin resistance in mice lacking the myotonic dystrophy protein kinase. 61 54
19482024 2009
17
Model for alternative splicing of insulin receptor in myotonic dystrophy type 1. 61 54
19902080 2009
18
Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. 61 54
19345584 2009
19
Analysis of repetitive regions in myotonic dystrophy type 1 and 2. 54 61
19360700 2009
20
Ribonuclear inclusions as biomarker of myotonic dystrophy type 2, even in improperly frozen or defrozen skeletal muscle biopsies. 54 61
19683984 2009
21
Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia. 61 54
19208413 2009
22
A Z-DNA sequence reduces slipped-strand structure formation in the myotonic dystrophy type 2 (CCTG) x (CAGG) repeat. 54 61
19218442 2009
23
Alternative splicing of RyR1 alters the efficacy of skeletal EC coupling. 61 54
19131108 2009
24
[MyoD mRNA expression in skeletal muscle of patients with myotonic dystrophy]. 54 61
19567095 2009
25
Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle. 54 61
19095965 2009
26
Analysis of Single Nucleotide Polymorphisms (SNPs) of the small-conductance calcium activated potassium channel (SK3) gene as genetic modifier of the cardiac phenotype in myotonic dystrophy type 1 patients. 61 54
19472917 2008
27
Colocalization of ribonuclear inclusions with muscle blind like-proteins in a family with myotonic dystrophy type 2 associated with a short CCTG expansion. 61 54
18804219 2008
28
High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. 54 61
18807109 2008
29
Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. 61 54
18583094 2008
30
A putative role of ribonuclear inclusions and MBNL1 in the impairment of gallbladder smooth muscle contractility with cholelithiasis in myotonic dystrophy type 1. 61 54
18653337 2008
31
HSPB2/MKBP, a novel and unique member of the small heat-shock protein family. 54 61
18615620 2008
32
Myotonic disorders. 61 54
18974556 2008
33
Characterization of the interaction of phorbol esters with the C1 domain of MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase) alpha/beta. 61 54
18263588 2008
34
Drosophila muscleblind is involved in troponin T alternative splicing and apoptosis. 54 61
18286170 2008
35
Myotonic dystrophy type 2 in Japan: ancestral origin distinct from Caucasian families. 61 54
18057971 2008
36
Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms. 61 54
17549748 2008
37
The hypocretin neurotransmission system in myotonic dystrophy type 1. 61 54
18195268 2008
38
Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. 61 54
18037882 2007
39
Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. 54 61
17728322 2007
40
Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. 61 54
17987120 2007
41
Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle. 54 61
17661063 2007
42
Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles. 61 54
17825047 2007
43
Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy. 61 54
17487865 2007
44
Regulation of the promoter of CUG triplet repeat binding protein, Cugbp1, during myogenesis. 54 61
17531403 2007
45
Co-operative Cdc42 and Rho signalling mediates ephrinB-triggered endothelial cell retraction. 54 61
17300218 2007
46
The nondystrophic myotonias. 61 54
17395134 2007
47
Elevated FMR1 mRNA in premutation carriers is due to increased transcription. 54 61
17283214 2007
48
Regulation of chloride ion conductance during skeletal muscle development and in disease. Focus on "Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1". 61 54
17215330 2007
49
Myotonic dystrophy: emerging mechanisms for DM1 and DM2. 61 54
16876389 2007
50
Inheritance of a novel RYR1 mutation in a family with myotonic dystrophy type 1. 54 61
17204054 2007

Variations for Myotonic Dystrophy

ClinVar genetic disease variations for Myotonic Dystrophy:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DMPK NM_004409.5(DMPK):c.643G>A (p.Gly215Ser)SNV Uncertain significance 496654 rs747348407 19:46281417-46281417 19:45778159-45778159
2 DMPK NM_004409.5(DMPK):c.1697C>T (p.Pro566Leu)SNV Uncertain significance 548605 rs536277584 19:46274269-46274269 19:45771011-45771011
3 DMPK NM_004409.5(DMPK):c.1477C>T (p.Arg493Cys)SNV Likely benign 496650 rs78771765 19:46275054-46275054 19:45771796-45771796

Expression for Myotonic Dystrophy

Search GEO for disease gene expression data for Myotonic Dystrophy.

Pathways for Myotonic Dystrophy

GO Terms for Myotonic Dystrophy

Cellular components related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actomyosin GO:0042641 8.62 CDC42BPB CDC42BPA

Biological processes related to Myotonic Dystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA processing GO:0006397 9.56 MBNL3 MBNL2 MBNL1 CELF1
2 RNA splicing GO:0008380 9.46 MBNL3 MBNL2 MBNL1 CELF1
3 actomyosin structure organization GO:0031032 9.32 CDC42BPB CDC42BPA
4 regulation of alternative mRNA splicing, via spliceosome GO:0000381 9.26 MBNL3 MBNL2 MBNL1 CELF1
5 regulation of RNA splicing GO:0043484 8.92 MBNL3 MBNL2 MBNL1 CELF1

Sources for Myotonic Dystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....